ArticleCancer discovery2020
Poly(ADP-ribose) Glycohydrolase Inhibition Sequesters NAD
Open access · bronzeAbstract read
In one paragraph
Article in Cancer discovery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
7.1field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 97 citations in OpenAlex.
- FET proteins and PARylation-dependent condensates promote replication fork reversal and genome stability.Nature communications · 2026Article
- CHD1L maintains genome integrity by facilitating okazaki fragment maturation.Nucleic acids research · 2026Article
- PARP inhibitors target cellular energy metabolism: Mechanisms of action and clinical implications.Translational oncology · 2026Review
- Anticancer sensitivities and biological characteristics of HCT116 cells resistant to the selective poly(ADP-ribose) glycohydrolase inhibitor.FEBS open bio · 2026Article
- Overcoming temozolomide resistance in glioma: recent advances and mechanistic insights.Acta neuropathologica communications · 2025Review
- Prospects for PARG inhibitors in cancer therapy.Journal of molecular cell biology · 2025Review
- Suppression of ADP-ribosylation reversal triggers cell vulnerability to alkylating agents.Neoplasia (New York, N.Y.) · 2025Article
- The power and the promise of epigenetic drugs in oncology.Frontiers in genetics · 2025Review
- PARG inhibitor sensitivity correlates with accumulation of single-stranded DNA gaps in preclinical models of ovarian cancer.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD+ Depletion.Molecular cancer research : MCR · 2024Article
- DNA damage response in breast cancer and its significant role in guiding novel precise therapies.Biomarker research · 2024Review
- Translational Research Platform for Malignant Central Nervous System Tumors.Neurologia medico-chirurgica · 2024Article
- Intrinsic PARG inhibitor sensitivity is mimicked byNAR cancer · 2024Article
- DNA damage response in brain tumors: A Society for Neuro-Oncology consensus review on mechanisms and translational efforts in neuro-oncology.Neuro-oncology · 2024Review
- Article
- Article
- Treatment of IDH-mutant glioma in the INDIGO era.NPJ precision oncology · 2024Review
- CDKN2A/B Homozygous Deletion Sensitizes IDH-Mutant Glioma to CDK4/6 Inhibition.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunity.Science (New York, N.Y.) · 2024Article
- Article
Corrections and comments
- Commented on by
Authors and funding
10 authors at 3 institutions in 2 countries.
Hiroaki NagashimaTranslational Neuro-Oncology Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Christine K LeeTranslational Neuro-Oncology Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Kensuke TateishiDepartment of Neurosurgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan.ORCID https://orcid.org/0000-0001-6895-9013
Fumi HiguchiDepartment of Neurosurgery, Dokkyo Medical University, Mibu, Tochigi, Japan.
Megha SubramanianTranslational Neuro-Oncology Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Seamus RaffertyTranslational Neuro-Oncology Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Lisa MelamedTranslational Neuro-Oncology Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Julie J MillerTranslational Neuro-Oncology Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. cahill@mgh.harvard.edu hwakimoto@mgh.harvard.edu julie.miller@mgh.harvard.edu.ORCID https://orcid.org/0000-0002-1288-593X
Hiroaki WakimotoTranslational Neuro-Oncology Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. cahill@mgh.harvard.edu hwakimoto@mgh.harvard.edu julie.miller@mgh.harvard.edu.ORCID https://orcid.org/0000-0001-8225-241X
Daniel P CahillTranslational Neuro-Oncology Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. cahill@mgh.harvard.edu hwakimoto@mgh.harvard.edu julie.miller@mgh.harvard.edu.
Massachusetts General Hospital · USDokkyo Medical University · JPYokohama City University · JP
Funding
Targeting the Vasular SystemP50CA165962 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI KEITH LLOYD LIGON · 2013 to 2026
$33.5MTraining Program in Nervous System TumorsK12CA090354 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI PLOTKIN, SCOTT R · 2001 to 2025
$16.3MTargeting Nicotinamide Adenine Dinucleotide (NAD+) metabolism in IDH mutant gliomasR01CA227821 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI CAHILL, DANIEL P., WAKIMOTO, HIROAKI · 2018 to 2022
$2.4MNCI NIH HHS K12 CA090354NCI NIH HHS P50 CA165962NCI NIH HHS R01 CA227821
Abstract
NAD
Indexed as
Antineoplastic Agents, AlkylatingGlycoside HydrolasesHumansNADTumor Cells, CulturedAntineoplastic Agents, AlkylatingGlycoside HydrolasesNADpoly ADP-ribose glycohydrolase
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.